010-84476011
肿瘤

HER2和TOP2A有预测蒽醌类化疗方案的价值(The Lancet Oncology, Volume 12, Issue 12, Pages 1134 - 1142, November 2011;doi:10.1016/S1470-2045(11)70231-5 ;Published Online: 13 September 2011)

分享:

HER2和TOP2A有预测蒽醌类化疗方案的价值(The Lance…

题目:用HER2和TOP2A预测包含蒽醌类的化疗方案辅助治疗乳腺癌的效果:一项关于个体患者数据的荟萃分析(HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of ind...

VEGFR3和CYP3A5*1的基因多态性与对舒尼替尼疗效及耐受性相关(The Lancet Oncology, Volume 12, Issue 12, Pages 1143 - 1150, November 2011;doi:10.1016/S1470-2045(11)70266-2 ;Published Online: 18 October 2011)

分享:

VEGFR3和CYP3A5*1的基因多态性与对舒尼替尼疗效及耐…

题目:单核苷酸基因多态性与接受一线舒尼替尼治疗的晚期肾细胞癌患者的反应及毒性作用的关系:一项多中心、观察性、前瞻性研究(Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma trea...

单用来曲唑比单用他莫昔芬以及序贯治疗能好降低乳腺癌的复发率和死亡率(The Lancet Oncology, Volume 12, Issue 12, Pages 1101 - 1108, November 2011)

分享:

单用来曲唑比单用他莫昔芬以及序贯治疗能好降低乳腺…

题目:单独及序贯使用来曲唑和他莫昔芬治疗绝经期后甾体激素受体阳性妇女的乳腺癌:中位随访期为8.1年的BIG 1-98随机临床试验(Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive brea...

SMILE化疗对新确诊的IV期、复发或难治性ENKL有效(J Clin Oncol. 2011 Nov 20;29(33):4410-6.)

分享:

SMILE化疗对新确诊的IV期、复发或难治性ENKL有效(J…

题目:SMILE化疗用于新确诊的IV期、复发或难治性结节外自然杀伤/T细胞淋巴瘤的2期研究:NK细胞肿瘤的研究小组研究(Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, ...

治疗性接种TG4010疫苗能提高晚期NSCLC的化疗效果(The Lancet Oncology, Volume 12, Issue 12, Pages 1125 - 1133, November 2011)

分享:

治疗性接种TG4010疫苗能提高晚期NSCLC的化疗效果(T…

题目:治疗性接种TG4010疫苗结合一线化疗治疗晚期非小细胞肺癌:一项2B期对照试验(Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial) 背景:化疗是晚期非小细胞肺癌(NSCL...

SOD2和IL13的SNPs可以作为直肠癌术前化疗反应的预测指标(The Pharmacogenomics Journal (2011) 11, 437–443)

分享:

SOD2和IL13的SNPs可以作为直肠癌术前化疗反应的预测…

题目:使用大规模候选基因筛选方法确定SOD2和IL13中可以做为直肠癌术前化疗反应预测指标的SNPs(A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer) ...

慢性髓样白血病患者:伊马替尼后检测低水平BCR-ABL1突变可指导后续治疗方案的选择(J Clin Oncol 29(32): 4250-4259)

分享:

慢性髓样白血病患者:伊马替尼后检测低水平BCR-ABL1…

题目:慢性髓样白血病患者伊马替尼耐药后敏感检测BCR-ABL1突变可预测随后的治疗结果(Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy) 目...

NQO1和NQO2多态性可影响乳腺癌患者对多柔比星和环磷酰胺辅助化疗的反应(Pharmacogenet Genomics. 2011 Dec;21(12):808-19.)

分享:

NQO1和NQO2多态性可影响乳腺癌患者对多柔比星和环磷…

题目: NQO1和NQO2位点的两个等位基因可以预测乳腺癌患者对多柔比星和环磷酰胺辅助化疗的反应(Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy) 目的:醌氧化物还原酶(...

腹腔化疗能提高晚期卵巢癌患者的总生存期和无进展生存期(Cochrane Database of Systematic Reviews DOI:10.1002/14651858.CD005340.pub3)

分享:

腹腔化疗能提高晚期卵巢癌患者的总生存期和无进展生…

题目:腹膜腔内化疗作为原发性卵巢上皮癌的初步治疗(Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.) 背景:卵巢癌往往对化疗敏感,并且在其自然史中多局限于腹腔表面。这些特点显然使其成为腹腔内(IP)化疗的...

外套细胞淋巴瘤老年患者:一线化疗方案中添加利妥昔单抗可改善生存率(Blood 118(18): 4808-4816)

分享:

外套细胞淋巴瘤老年患者:一线化疗方案中添加利妥昔…

题目:单独化疗方案中添加利妥昔单抗作为一线治疗可改善外套细胞淋巴瘤老年患者的整体生存率(Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma) 临床试验已经证明,...

首页上一页252253254255256257258下一页尾页共2628篇文章/共263页

现在注册

联系我们